AstraZeneca’s Imfinzi/Lynparza Regimens Granted EC Approval to Treat Endometrial Cancer

AstraZeneca’s Imfinzi/Lynparza Regimens Granted EC Approval to Treat Endometrial Cancer

By, Admin 22 August 2024

Overview

AstraZeneca’s (AZ) anti-PDL1 antibody Imfinzi (durvalumab) and PARP inhibitor Lynparza (olaparib) have been approved by the European Commission (EC) to treat certain cases of endometrial cancer.

Imfinzi Plus Approval

  • The EU regulator has approved Imfinzi plus chemotherapy as a first-line treatment, followed by Lynparza and Imfinzi, for use in patients with mismatch repair proficient (pMMR) primary advanced or recurrent endometrial cancer.
  • Imfinzi plus chemotherapy, followed by Imfinzi alone, has also been authorised to treat those with mismatch repair deficient (dMMR) disease.

Recommendation from EMA

The EC’s decision follows a recent recommendation from the European Medicines Agency’s human medicines committee and was based on positive results from the late-stage DUO-E trial.

Subgroup Analysis Data

A pre-specified exploratory subgroup analysis of the study demonstrated a 43% reduction in the risk of disease progression or death for pMMR patients receiving the Lynparza/Imfinzi combination compared to the control arm, while the Imfinzi regimen reduced the risk of disease progression or death in the dMMR cohort by 58% versus control.

Safety profiles: - The safety profiles of both regimens were generally manageable, well tolerated and broadly consistent with the known profiles of the individual agents, AZ said.

About Endometrial Cancer 

  • Endometrial cancer is the fourth most common cancer in women in Europe, with nearly 125,000 diagnoses made in 2022.
  • The majority of patients with endometrial cancer are diagnosed at an early stage, at which point the five-year survival rate is as high as 90%. 
  • However, this falls to less than 20% for those with advanced disease.

Words from DUO-E trial Investigator

  •  DUO-E trial investigator Els Van Nieuwenhuysen, UZ Leuven, said: “This approval is welcome news for patients with advanced or recurrent endometrial cancer in Europe, especially those with pMMR disease who have limited options.
  • The [Lynparza] and [Imfinzi] as well as the [Imfinzi] regimens now have the potential to improve outcomes for all patients in this setting in Europe, regardless of mismatch repair status.

Regulatory submissions for Imfinzi and Lynparza are currently under review in several other countries based on the DUO-E study, AZ said.

The EU approval came in the same week that an Imfinzi/chemotherapy regimen was approved by the US Food and Drug Administration to treat a subset of adults with resectable non-small cell lung cancer.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!